Mexico Continuous Glucose Monitoring (CGM) Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Application (Diabetic Patients, Critical Patients), And By End User Industry (Hospitals, Diagnostic Centers And Clinics, Home Care) - Forecasts From 2023 To 2028

  • Published : Apr 2023
  • Report Code : KSI061615170
  • Pages : 72

The Mexico CGM market is expected to grow at a CAGR of 12.93%, from an initial value of US$32.027 million in 2021 to US$75.015 million by 2028.

Continuous sugar monitoring (CGM), sometimes referred to as sugar continuous glucose monitoring, automatically monitors blood glucose throughout the day. Making more educated choices about maintaining daily medication use, a healthy diet, and physical activity can be aided with real-time glucose monitoring. A small sensor used in CGM is implanted beneath the skin, often on the arm or abdomen. The sensor picks up interstitial glucose, which is present in the intercellular fluid. The sensor examines the glucose level every few minutes, and wireless data transmission sends the results to a monitor.

Moreover, the closed-loop bionic/artificial pancreas has been given a blueprint because of CGMS-based technologies. Thus, businesses that manufacture glucose monitoring devices concentrate largely on creating novel and cutting-edge CGMS. It has several applications for healthcare settings (hospital ICUs, diagnostic centers, and clinics), for all age groups, and geographical locations. A growing awareness of diabetes preventative care, new product debuts, government efforts, and the CGM device market are the major market drivers for CGM Market.

Throughout the projected period, technological developments to increase sensor accuracy are anticipated to fuel market expansion. IDF asserts that a range of socioeconomic, demographic, environmental, and genetic variables, such as urbanization, declining levels of physical activity, and rising rates of overweight and obesity, are to blame for the increase in type 2 diabetes cases in Mexico. For the convenience of diabetic patients, continuous glucose monitoring has grown to be a popular substitute for portable finger-prick glucometers already on the market in Mexico.

Increasing patients with Type-1 diabetes in Mexico to surge growth.

Mexico now ranks in the top 10 nations or territories in terms of total health expenditure, with diabetes-related medical costs exceeding USD 20 billion. Over half of the diabetics in the country (47.5%) have undiagnosed diabetes. If diabetes is not adequately diagnosed or managed, patients run the danger of serious and sometimes fatal consequences like heart attack, stroke, kidney failure, blindness, and lower limb amputation. As a result, people have a worse quality of life, spend more money on healthcare, and need access to treatment more frequently. Given that Type 2 diabetes is the top cause of mortality for women and the second leading cause of death for men in Mexico, it has become a burden on the healthcare system. Diabetes is a disease that can be brought on by obesity, sedentarism, bad eating habits, genetics, family history, and age. The aforementioned elements are thus anticipated to boost the Mexican market's expansion.

Better healthcare coverage by pharmacies to surge growth.

In Mexico, pharmacies are seen as a key instrument for improving healthcare coverage. Technology tools have been implemented in the pharmaceutical sector. Companies who participate in the "Beyond the Pills" campaign add digital platforms to their drug treatment programs to encourage follow-up and guarantee treatment continuation. One of the businesses utilizing the Beyond the Pills method to treat diabetes is Roche. MySugr is a digital platform used by the pharmaceutical business to control diabetes. To meet unmet requirements, Roche can do so by providing openly available patient solutions. It seeks to assist diabetics in improving their quality of life by helping them spend more time inside their optimum glucose target range.

Market Key Developments

  • In March 2023, FDA approved the FreeStyle Libre 2 and FreeStyle Libre 3 modified CGM (continuous glucose monitoring) system sensors as said by Abbott Laboratories for connection with automated insulin delivery (AID) systems.
  • In November 2022, By offering in-office and at-home insertion options for the Eversense® E3 Continuous Glucose Monitoring System, Senseonics and Ascensia announce a collaboration with the nurse practitioner group (CGM).

Mexico Continuous Glucose Monitoring (CGM) Market Scope:

 

Report Metric Details
Market Size Value in 2021 US$32.027 million
Market Size Value in 2028 US$75.015 million
Growth Rate CAGR of 12.93% from 2021 to 2028
Base Year 2021
Forecast Period 2023 – 2028
Forecast Unit (Value) USD Million
Segments Covered Application and End-User Industry
Companies Covered Dexcom, Inc., Abbott Laboratories, Medtronic plc, Roche Diabetes Care, Inc., Senseonics Holdings, Inc., Ascensia Diabetes Care, Insulet Corporation, Tandem Diabetes Care, Inc., GlySens Incorporated
Customization Scope Free report customization with purchase

 

Segmentation:

  • By Application
    • Diabetes Patients
    • Critical Patients
  • By End-User Industry
    • Hospitals
    • Diagnostic Centers & Clinics
    • Home Care

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY  

2.1. Research Data

2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. MEXICO CONTINUOUS GLUCOSE MONITORING (CGM) MARKET, BY APPLICATION

5.1. Introduction

5.2. Diabetes Patients

5.3. Critical Patients

6. MEXICO CONTINUOUS GLUCOSE MONITORING (CGM) MARKET, BY END-USER INDUSTRY

6.1. Introduction

6.2. Hospitals

6.3. Diagnostic Centers & Clinics

6.4. Home Care

7. COMPETITIVE ENVIRONMENT AND ANALYSIS

7.1. Major Players and Strategy Analysis

7.2. Emerging Players and Market Lucrativeness

7.3. Mergers, Acquisitions, Agreements, and Collaborations

7.4. Vendor Competitiveness Matrix

8. COMPANY PROFILES

8.1. Dexcom, Inc.

8.2. Abbott Laboratories

8.3. Medtronic plc

8.4. Roche Diabetes Care, Inc.

8.5. Senseonics Holdings, Inc.

8.6. Ascensia Diabetes Care

8.7. Insulet Corporation

8.8. Tandem Diabetes Care, Inc.

8.9. GlySens Incorporated


Dexcom, Inc.

Abbott Laboratories

Medtronic plc

Roche Diabetes Care, Inc.

Senseonics Holdings, Inc.

Ascensia Diabetes Care

Insulet Corporation

Tandem Diabetes Care, Inc.

GlySens Incorporated